Article
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
The oncologist - 1 Feb 2020
Da Vià Matteo Claudio, Solimando Antonio Giovanni, Garitano-Trojaola Andoni, Barrio Santiago, Munawar Umair, Strifler Susanne, Haertle Larissa, Rhodes Nadine, Teufel Eva, Vogt Cornelia, Lapa Constantin, Beilhack Andreas, Rasche Leo, Einsele Hermann, Kortüm K Martin
Abstract excerpt
Combined MEK-BRAF inhibition is a well-established treatment strategy in BRAF-mutated cancer, most prominently in malignant melanoma with durable responses being achieved through this targeted therapy. However, a subset of patients face primary unresponsiveness despite presence of the activating mutation at position V600E, and others acquire resistance under treatment. Underlying resistance mechanisms are largely...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.